Analysts Offer Predictions for IDYA FY2024 Earnings

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Cantor Fitzgerald issued their FY2024 earnings estimates for IDEAYA Biosciences in a report released on Wednesday, October 16th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings per share of ($2.26) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($2.51) per share.

IDYA has been the topic of several other reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $61.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, September 24th. BTIG Research lifted their price target on IDEAYA Biosciences from $55.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday, July 9th. Oppenheimer lowered their price objective on IDEAYA Biosciences from $60.00 to $53.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Wedbush cut their target price on shares of IDEAYA Biosciences from $54.00 to $52.00 and set an “outperform” rating for the company in a report on Tuesday, September 24th. Finally, Stifel Nicolaus raised their price target on shares of IDEAYA Biosciences from $63.00 to $68.00 and gave the company a “buy” rating in a research report on Tuesday, September 10th. Thirteen research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $56.00.

IDEAYA Biosciences Trading Down 1.0 %

IDYA opened at $30.69 on Friday. IDEAYA Biosciences has a 12-month low of $23.41 and a 12-month high of $47.74. The firm has a 50 day moving average of $35.08 and a two-hundred day moving average of $37.95. The firm has a market capitalization of $2.32 billion, a PE ratio of -15.27 and a beta of 0.82.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.14). During the same quarter last year, the business earned ($0.50) earnings per share.

Institutional Investors Weigh In On IDEAYA Biosciences

Several institutional investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. lifted its position in shares of IDEAYA Biosciences by 5.3% in the first quarter. Ameritas Investment Partners Inc. now owns 6,562 shares of the company’s stock valued at $288,000 after acquiring an additional 332 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in IDEAYA Biosciences by 4.4% in the 1st quarter. Principal Financial Group Inc. now owns 15,275 shares of the company’s stock valued at $670,000 after purchasing an additional 648 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in IDEAYA Biosciences by 38.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,340 shares of the company’s stock worth $117,000 after purchasing an additional 927 shares during the last quarter. Covestor Ltd grew its holdings in shares of IDEAYA Biosciences by 9,225.0% during the first quarter. Covestor Ltd now owns 1,119 shares of the company’s stock worth $49,000 after buying an additional 1,107 shares in the last quarter. Finally, Quest Partners LLC acquired a new stake in shares of IDEAYA Biosciences in the second quarter valued at about $41,000. 98.29% of the stock is currently owned by institutional investors and hedge funds.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.